Eisai Buys Alzheimer’s Disease Research Data From TorreyPines
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai said Nov. 11 it signed an agreement with California-based TorreyPines Therapeutics to purchase all research data and assets from TorreyPines' research activities on genes associated with late-onset Alzheimer's disease for an undisclosed upfront payment
You may also be interested in...
Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 1 Of 2)
TOKYO - Swedish startup BioArctic Neuroscience CEO Pär Gellerfors wondered who was calling him at 8 a.m. one June morning back in 2003.
Rethinking Alzheimer's: Mapping Out an Approval Process
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).